GlassScriptPhysician profile
Christopher S Acree
NPI 1629013032
$3,722.67
in general payments reported to CMS, 2019-2025
24 companies · $737 in 2025
The $737 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,065 · 2022: $453 · 2023: $592 · 2024: $875 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,075 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,075.40 |
| Education | $129.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,202.25 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Astrazeneca Pharmaceuticals LP | $690.67 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $343.14 | 2021-2024 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $260.71 | 2023-2025 | |
| Amarin Pharma, INC. | $166.43 | 2021 | |
| Galt Pharmaceuticals, LLC | $148.27 | 2023 | Orphengesic Forte, Oravig |
| Pfizer INC. | $128.86 | 2021 | |
| Ucb, INC. | $124.79 | 2025 | Bimzelx |
| Merz Pharmaceuticals, LLC | $106.21 | 2021-2022 | |
| Lilly USA, LLC | $103.55 | 2022-2025 | Zepbound, Mounjaro |
| Allergan, INC. | $71.80 | 2021-2022 | |
| Exact Sciences Corporation | $69.67 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Gilead Sciences, INC. | $54.24 | 2025 | |
| Orthofix Medical, INC. | $39.19 | 2025 | Physio-Stim |
| Jazz Pharmaceuticals INC. | $32.53 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $30.04 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $26.59 | 2021 | |
| Eisai INC. | $22.25 | 2021 | |
| Genentech USA, INC. | $21.83 | 2021 | |
| Leo Pharma INC. | $20.40 | 2021 | |
| Mimedx Group, INC. | $18.62 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $15.83 | 2025 | |
| Avanir Pharmaceuticals, INC. | $13.29 | 2021 | |
| Horizon Therapeutics Plc | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Acree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.